Psyence Group Announces Resignation of Board Member
TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derive...
Psyence Group Inc., a life science biotechnology company, engages in the cultivation and production of commercial psilocybin mushroom. It operates in two segments: Clinical Trial Activities and Non-Clinical Trial Activities. The company natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. The company was founded in 2019 and is based in Toronto, Canada.
0.0085 | |
0.0085 | |
- | |
0.0085 | |
0.0085 | |
0.008-0.1676 | |
1 522 K | |
140 M | |
5 541 | |
0.0005 | |
2.051 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derive...
TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wel...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: